Immune-related adverse events associated with immune checkpoint inhibitors in patients with cancer.
CONCLUSION: With the increased use of immunotherapeutic agents, increased awareness and early recognition are required for effective management of irAEs. Our experience as a single institution might be of use for health care providers in oncology.
PMID: 32935638 [PubMed - as supplied by publisher]
Source: Tumori - Category: Cancer & Oncology Tags: Tumori Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Health Management | Hepatitis | Hypothyroidism | Laboratory Medicine | Toxicology